Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 41 clinical trials
Safety Tolerability and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma

This is a Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of VCN-01 in Combination With Durvalumab (MEDI4736) in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of

durvalumab
monoclonal antibodies
dental caries
liver metastasis
caries
  • 4 views
  • 25 Jan, 2021
  • 2 locations
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

with this condition receive if they are not part of a clinical study. Combination therapies studied in this trial include MEDI4736 (durvalumab) plus olaparib and cediranib, durvalumab and cediranib, or

  • 0 views
  • 22 Sep, 2021
  • 258 locations
Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as nab-paclitaxel, work in different …

  • 0 views
  • 02 Sep, 2021
  • 11 locations
Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer

Single arm, Phase II trial of concurrent Durvalumab (MEDI 4736) and radiotherapy followed by consolidative Durvalumb (MEDI 4736) for Stage III Non-Small Cell Lung Cancer (NSCLC)

durvalumab
serum bilirubin level
follicle stimulating hormone
stage iii non-small cell lung cancer
cancer chemotherapy
  • 0 views
  • 12 Aug, 2021
  • 1 location
Testing the Combination of Olaparib and Durvalumab Cediranib and Durvalumab Olaparib and Capivasertib and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone and Olaparib Alone

This phase II trial studies the effects of the combination of olaparib and durvalumab, cediranib and durvalumab, olaparib and capivasertib, and cediranib alone in treating patients with endometrial cancer that has come back (recurrent) or does not respond to treatment (refractory). Olaparib, cediranib, and capivasertib may stop the growth of …

cytotoxic chemotherapy
non-target
tumor cells
luteinizing hormone
plain x-ray
  • 76 views
  • 19 Sep, 2021
  • 505 locations
Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance

Research Hypothesis Lung cancer is the leading cause of cancer-related mortality in France and in western countries, accounting for more than 1.8 million new cases and 1.5 million deaths worldwide in 2012. Recent advances in the management of patients with Non-small Cell Lung Cancer Patients (NSCLC) include the use of …

durvalumab
serum bilirubin level
lung carcinoma
docetaxel
growth factor
  • 0 views
  • 09 Apr, 2021
  • 1 location
Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab

Patients with cancer are increasingly being treated with drugs designed to modulate the response of their immune system, broadly to boost their body's defences against cancer. However, there is an unmet need to identify which patients are unlikely to benefit. Deciding on benefit from therapy uses standard imaging methods (e.g. …

  • 0 views
  • 24 Jan, 2021
  • 1 location
Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer

This phase-2 monocenter non-randomized prospective clinical trial evaluates the effectiveness of minimally invasive microwave ablation plus immunotherapy for unresectable non-metastatic locally advanced pancreatic cancer.

  • 0 views
  • 26 Jan, 2021
A Study of Durvalumab in Combination With Doxorubicin for Advanced Soft Tissue Sarcoma

The yearly incidence of soft-tissue sarcomas (STS) in the USA is roughly 11,280 cases, and metastatic STS have a median overall survival of about 12 months. Sarcomas of the soft tissue are a heterogeneous group of malignant tumors of mesenchymal origin that originate in connective tissue. Local control with wide …

advanced soft tissue sarcoma
cancer chemotherapy
olaratumab
metastatic sarcoma
doxorubicin
  • 1 views
  • 26 Jan, 2021
  • 1 location
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

This randomized phase I/II trial studies the best dose and side effects of durvalumab and to see how well it works with or without lenalidomide in treating patients with cutaneous or peripheral T cell lymphoma that has come back and does not respond to treatment. Monoclonal antibodies, such as durvalumab, …

durvalumab
lenalidomide
t-cell lymphoma
sezary syndrome
anaplastic large cell lymphoma
  • 60 views
  • 27 Feb, 2021
  • 4 locations